Catalent Biologics Expert To Discuss Assay Automation At Upcoming International Drug Discovery Science & Technology Conference
SOMERSET, N.J. – August 9, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Christopher Hepler, Group Leader, Biologics Analytical Services, Catalent Biologics has been invited to speak at the upcoming 16th Annual Congress of International Drug Discovery Science & Technology (IDDST), to be held at the Boston Marriott Cambridge, Boston, on Aug. 16 – 18, 2018.
Mr. Hepler’s presentation, on Thursday, Aug. 16 at 2:55 p.m., is entitled “Solutions for Automation of GMP Assays,” and will include several case studies highlighting the benefits of assay automation and detailing strategies to overcome challenges. Mr. Hepler will also explore future directions in automation, which are being explored at Catalent Biologics. Attendees will learn:
- the motivations for assay automation;
- the options available for automating different types of biologics assays;
- the challenges and potential solutions associated with assay automation.
Mr. Hepler is a 20-year veteran of the pharmaceutical and biopharmaceutical industry, and has extensive validation and project management experience operating under Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). He has expertise in protein purification, biochemical assays and laboratory automation. He holds a bachelor’s degree in animal science and a master’s degree in physiology, both from North Carolina State University.
For more information visit Catalent.com/IDDST.
To arrange a meeting with any of the attending Catalent executives at the event, contact Richard Kerns at NEPR – email@example.com
+44 (0)7580 041073
+44 (0) 161 728 5880
Catalent, Inc. (NYSE: CTLT), is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.